State Report: New Jersey
Commonwealth Fund State Performance Ranking (2007): 26
New Jersey needs an early warning system so it can identify acute-care hospitals in financial distress and intervene to ensure access to care, according to a January report released by Governor Jon S. Corzine's Commission on Rationalizing Healthcare Resources.
The report identified major causes of the industry's overall poor financial health:
STATE PROGRAMS
In September, a task force made 20 recommendations for improving the efficiency and cost-effectiveness of state health programs. The recommendations focus on the structure of insurance plans and on lowering the cost to the state of prescription drugs and long-term care.
Governor Corzine also signed legislation requiring general hospitals to implement infection prevention programs in their intensive care units. The legislation likewise requires hospitals to report cases of MRSA to the New Jersey Department of Health and Senior Services.
HMO MEASURES SLIDE
While New Jersey's six commercial HMOs have remained largely consistent in 12 clinical performance categories, customer satisfaction measures were mixed, according to the annual HMO report card. None of the other clinical measures changed by more than 2%, but there was marked change in several customer satisfaction categories
MHE Sources: CMS, Urban Institute, Kaiser Commission on Medicaid and the Uninsured, U.S. Census Bureau, The Commonwealth Fund.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Leadership Team at The Cigna Group Revamps in Efforts to Drive Growth, Enhance Customer Focus
March 13th 2025David M. Cordani, chairman and CEO of The Cigna Group, expressed that these moves were made to “build upon our strengths for continued growth, enhance our customer focus, and deliver even greater value for those we serve."
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
